NICE has recommended that Akcea’s hereditary transthyretin-related amyloidosis (hATTR) treatment Tegsedi be made available on the NHS in England, ahead of a rival therapy from Alnylam.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback